Stock Events

Stock Events

BriaCell Therapeutics

$3.30

67

+$0.00+0%Friday 00:30

Statistics

Day High

3.3

Day Low

3.3

52W High

4.26

52W Low

2.74

Volume

1

Avg. Volume

-

Mkt Cap

28.71M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Financials

-Profit Margin

Unprofitable

2020

2021

2022

2023

2024

2025

0Revenue

-26.31MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BCTX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Pfizer is involved in developing cancer immunotherapies, directly competing with BriaCell's focus on advanced breast cancer treatments.

Merck's strong presence in the oncology sector, especially with its blockbuster drug Keytruda, makes it a direct competitor in cancer treatment.

Bristol-Myers Squibb

Bristol Myers Squibb has a robust lineup of cancer drugs and is actively involved in developing immunotherapies, competing in the same space as BriaCell.

Gilead Sciences

Gilead Sciences, with its acquisition of Kite Pharma, has become a key player in the cancer immunotherapy market, competing with BriaCell's therapies.

Novartis is a major pharmaceutical company with a strong emphasis on oncology, including breast cancer treatments, making it a competitor.

Amgen's focus on innovative treatments for cancer places it in direct competition with BriaCell, especially in the development of biologics.

Roche, through its Genentech division, is a leader in cancer therapeutics, including breast cancer, competing with BriaCell's targeted approach.

AstraZeneca has a significant portfolio in oncology, including breast cancer treatments, making it a competitor in the same therapeutic area as BriaCell.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals' work in developing monoclonal antibodies for cancer treatment puts it in competition with BriaCell's immunotherapy approach.

Iovance Biotherapeutics

Iovance Biotherapeutics focuses on T-cell-based therapies for cancer, competing in the innovative immunotherapy space alongside BriaCell.

About

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Show More

CEO

ISIN

CA1079303071

Listings

0 Comments

Share your thoughts

FAQs

What is BriaCell Therapeutics stock price today?▼

The current price of BCTX.BOATS is $3.30 USD — it has increased by +0% in the past 24 hours. Watch BriaCell Therapeutics stock price performance more closely on the chart.

What is BriaCell Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange BriaCell Therapeutics stocks are traded under the ticker BCTX.BOATS.

What is BriaCell Therapeutics market cap?▼

Today BriaCell Therapeutics has the market capitalization of 28.71M

What is BriaCell Therapeutics revenue for the last year?▼

BriaCell Therapeutics revenue for the last year amounts to 0 USD.

What is BriaCell Therapeutics net income for the last year?▼

BCTX.BOATS net income for the last year is -26.31M USD.

In which sector is BriaCell Therapeutics located?▼

BriaCell Therapeutics operates in the Other sector.

When did BriaCell Therapeutics complete a stock split?▼

The last stock split for BriaCell Therapeutics was on August 25, 2025 with a ratio of 1:10.